SG11201807012QA - Acid addition salts of piperazine derivatives - Google Patents
Acid addition salts of piperazine derivativesInfo
- Publication number
- SG11201807012QA SG11201807012QA SG11201807012QA SG11201807012QA SG11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7d
- acid addition
- addition salts
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621006638 | 2016-02-25 | ||
| PCT/EP2017/054278 WO2017144637A1 (en) | 2016-02-25 | 2017-02-24 | Acid addition salts of piperazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807012QA true SG11201807012QA (en) | 2018-09-27 |
Family
ID=58159076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807012QA SG11201807012QA (en) | 2016-02-25 | 2017-02-24 | Acid addition salts of piperazine derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10696668B2 (es) |
| EP (1) | EP3419976B1 (es) |
| JP (1) | JP6971999B2 (es) |
| KR (1) | KR20180132060A (es) |
| CN (1) | CN109071526B (es) |
| AU (1) | AU2017222962B2 (es) |
| BR (1) | BR112018017225A2 (es) |
| CA (1) | CA3014572C (es) |
| EA (1) | EA201891438A1 (es) |
| ES (1) | ES2879351T3 (es) |
| MX (1) | MX2018010301A (es) |
| SG (1) | SG11201807012QA (es) |
| WO (1) | WO2017144637A1 (es) |
| ZA (1) | ZA201804870B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53944A (fr) | 2014-08-28 | 2021-08-25 | Asceneuron Sa | Inhibiteurs de la glycosidase |
| AU2017222962B2 (en) * | 2016-02-25 | 2021-03-25 | Asceneuron S. A. | Acid addition salts of piperazine derivatives |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| EP3419971B1 (en) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Glycosidase inhibitors |
| WO2018153508A2 (en) * | 2017-02-24 | 2018-08-30 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
| JP2020503298A (ja) | 2016-12-16 | 2020-01-30 | ヤンセン ファーマシューティカ エヌ．ベー． | 単環式ｏｇａ阻害剤化合物 |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| CA3103049A1 (en) * | 2018-06-21 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| HUE063226T2 (hu) * | 2018-08-22 | 2024-01-28 | Asceneuron Sa | Glikozidáz inhibitorokként használható piperazinszármazékok szukcinát és fumarát savaddíciós sói |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
| WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| CN114929337A (zh) | 2019-12-18 | 2022-08-19 | 詹森药业有限公司 | Oga抑制剂化合物 |
| WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| KR20220118483A (ko) | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | Oga 억제제 화합물 |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
| CA3223922A1 (en) * | 2021-07-05 | 2023-01-12 | Dirk Beher | Medicaments comprising glycosidase inhibitors |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1311316A (fr) | 1961-04-12 | 1962-12-07 | Science Union Et Compagnie Soc | Nouveaux dérivés de la pipérazine et leurs préparations |
| NL127996C (es) | 1963-11-19 | |||
| US3485757A (en) | 1964-11-23 | 1969-12-23 | Atomic Energy Commission | Thermoelectric composition comprising doped bismuth telluride,silicon and boron |
| DE1595923A1 (de) * | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung |
| GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
| US4600025A (en) | 1982-11-18 | 1986-07-15 | Grigg Ronald E | Smoking products comprising nicotine substitutes |
| AU675786B2 (en) | 1992-04-15 | 1997-02-20 | Merck Sharp & Dohme Limited | Azacyclic compounds |
| IL118768A (en) | 1995-07-12 | 2000-10-31 | Akzo Nobel Nv | Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation |
| TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| AU6852898A (en) | 1997-04-17 | 1998-11-11 | Takeda Chemical Industries Ltd. | Thermogenic composition and benzazepine thermogenics |
| EP1025097B1 (en) | 1997-10-24 | 2005-04-27 | Neurogen Corporation | 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d 4? receptor subtype ligands |
| MXPA03010612A (es) * | 2001-05-22 | 2004-04-02 | Neurogen Corp | Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos. |
| US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| CA2488635C (en) | 2002-06-12 | 2012-10-23 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| AU2003245753B2 (en) | 2002-07-05 | 2009-12-24 | Targacept, Inc. | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| EA009369B1 (ru) | 2002-09-09 | 2007-12-28 | Янссен Фармацевтика, Н.В. | Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором |
| CN1777584A (zh) | 2003-04-18 | 2006-05-24 | 伊莱利利公司 | 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物 |
| AU2004241213B2 (en) * | 2003-05-21 | 2009-04-23 | Banyu Pharmaceutical Co., Ltd. | 2-aminoquinoline derivative |
| MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
| US7253168B2 (en) | 2004-04-07 | 2007-08-07 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
| HU227119B1 (en) | 2004-07-29 | 2010-07-28 | Richter Gedeon Nyrt | Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| HUP0401522A2 (en) | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation |
| US20080287375A1 (en) | 2005-03-01 | 2008-11-20 | Simon Fraser University | Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof |
| TW200724140A (en) | 2005-05-27 | 2007-07-01 | Eisai Co Ltd | Hydantoin compounds |
| WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| KR20080111015A (ko) | 2006-03-31 | 2008-12-22 | 아스트라제네카 아베 | 비시클릭 벤즈이미다졸 화합물 및 대사성 글루타메이트 수용체 증강체로서 이들의 용도 |
| CN101448827A (zh) | 2006-05-22 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 吲哚衍生物 |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| US8334310B2 (en) | 2006-08-31 | 2012-12-18 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20100022517A1 (en) | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2009011904A1 (en) | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| PL2215075T3 (pl) | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| JP2011518145A (ja) | 2008-04-17 | 2011-06-23 | ファイザー・インク | Ｆａａｈ阻害剤として有用な４−［３−（アリールオキシ）ベンジリデン］−３−メチルピペリジン５員アリールカルボキサミド化合物 |
| JP2011518142A (ja) | 2008-04-17 | 2011-06-23 | ファイザー・インク | Ｆａａｈ阻害剤として有用なエーテルベンジリデンピペリジン５員アリールカルボキサミド化合物 |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| WO2010021381A1 (ja) | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| CA2735269C (en) | 2008-08-29 | 2018-10-16 | Saint Mary's University | Use of gluconacetobacter with reduced use of nitrogen fertilizer to improve beet crop production |
| EP2336104A4 (en) | 2008-09-02 | 2012-01-25 | Nissan Chemical Ind Ltd | ORTHO-SUBSTITUTED HALOGENOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE |
| TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| AU2010221417A1 (en) | 2009-03-02 | 2011-09-22 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| WO2010108115A1 (en) | 2009-03-20 | 2010-09-23 | Sanford-Burnham Medical Research Institute | Allosteric jnk inhibitors |
| US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2010270034A (ja) | 2009-05-20 | 2010-12-02 | Sumitomo Chemical Co Ltd | アミド化合物並びにその植物病害防除用途 |
| EP2445340B1 (en) | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| JP2013537233A (ja) | 2010-09-17 | 2013-09-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 脂肪酸合成酵素阻害剤 |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| JP5861194B2 (ja) | 2010-12-23 | 2016-02-16 | アレクトス・セラピューティクス・インコーポレイテッド | 選択的グルコシダーゼインヒビターおよびその使用 |
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| US9035059B2 (en) | 2011-03-14 | 2015-05-19 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing condensed heterocyclic compound |
| DK2748171T3 (en) | 2011-08-25 | 2016-05-09 | Merck Patent Gmbh | PYRANO [3,2-D] [1,3] THIAZOL AS GLYCOSIDASE INHIBITORS |
| US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| PT2882733T (pt) | 2012-08-08 | 2017-07-13 | Novartis Tiergesundheit Ag | Azinas substituídas como pesticidas |
| EP2890678A4 (en) | 2012-08-31 | 2016-01-27 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| WO2014159234A1 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Glycosidase inhibitors |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| UA117040C2 (uk) | 2013-12-05 | 2018-06-11 | Пфайзер Інк. | ПІРОЛО[2,3-d]ПІРИМІДИНІЛ-, ПІРОЛО[2,3-b]ПІРАЗИНІЛ- ТА ПІРОЛО[2,3-d]ПІРИДИНІЛАКРИЛАМІДИ |
| EP2913330A1 (en) | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
| MA50375A (fr) | 2014-04-23 | 2021-05-26 | Dart Neuroscience Cayman Ltd | Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 |
| MA53944A (fr) * | 2014-08-28 | 2021-08-25 | Asceneuron Sa | Inhibiteurs de la glycosidase |
| MX2017016788A (es) | 2015-07-02 | 2018-07-06 | Janssen Sciences Ireland Uc | Compuestos antibacterianos. |
| BR112018008431A2 (pt) | 2015-11-02 | 2018-11-06 | Janssen Pharmaceutica Nv | composto de [1,2,4]triazolo[1,5-a]pirimidin-7-il |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| ES2893613T3 (es) | 2015-11-25 | 2022-02-09 | Lieber Inst Inc Dba Lieber Inst For Brain Development | Tetrahidro-8H-pirido[1,2-a]pirazin-8-onas como inhibidores de COMT para el tratamiento de trastornos neurodegenerativos |
| WO2017106254A1 (en) | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419971B1 (en) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Glycosidase inhibitors |
| MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| AU2017222962B2 (en) * | 2016-02-25 | 2021-03-25 | Asceneuron S. A. | Acid addition salts of piperazine derivatives |
| WO2018153508A2 (en) | 2017-02-24 | 2018-08-30 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
| EA201891437A1 (ru) | 2016-02-25 | 2019-03-29 | Асенейрон С. А. | Способ разделения энантиомеров пиперазиновых производных |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| JP2020503298A (ja) | 2016-12-16 | 2020-01-30 | ヤンセン ファーマシューティカ エヌ．ベー． | 単環式ｏｇａ阻害剤化合物 |
| EP3555094A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Bicyclic oga inhibitor compounds |
| AR110747A1 (es) | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
| MA47420A (fr) | 2017-02-06 | 2019-12-11 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| AR111693A1 (es) | 2017-05-25 | 2019-08-07 | Lilly Co Eli | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| HUE063226T2 (hu) | 2018-08-22 | 2024-01-28 | Asceneuron Sa | Glikozidáz inhibitorokként használható piperazinszármazékok szukcinát és fumarát savaddíciós sói |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
-
2017
- 2017-02-24 AU AU2017222962A patent/AU2017222962B2/en active Active
- 2017-02-24 BR BR112018017225A patent/BR112018017225A2/pt active IP Right Grant
- 2017-02-24 CA CA3014572A patent/CA3014572C/en active Active
- 2017-02-24 KR KR1020187027133A patent/KR20180132060A/ko not_active Application Discontinuation
- 2017-02-24 ES ES17707011T patent/ES2879351T3/es active Active
- 2017-02-24 JP JP2018544534A patent/JP6971999B2/ja active Active
- 2017-02-24 EP EP17707011.7A patent/EP3419976B1/en active Active
- 2017-02-24 SG SG11201807012QA patent/SG11201807012QA/en unknown
- 2017-02-24 US US16/079,162 patent/US10696668B2/en active Active
- 2017-02-24 MX MX2018010301A patent/MX2018010301A/es unknown
- 2017-02-24 CN CN201780013496.8A patent/CN109071526B/zh active Active
- 2017-02-24 WO PCT/EP2017/054278 patent/WO2017144637A1/en active Application Filing
- 2017-02-24 EA EA201891438A patent/EA201891438A1/ru unknown
-
2018
- 2018-07-19 ZA ZA2018/04870A patent/ZA201804870B/en unknown
-
2020
- 2020-05-18 US US16/877,284 patent/US11591327B2/en active Active
-
2022
- 2022-12-06 US US18/062,295 patent/US20230120169A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200385375A1 (en) | 2020-12-10 |
| JP2019506429A (ja) | 2019-03-07 |
| US20230120169A1 (en) | 2023-04-20 |
| MX2018010301A (es) | 2019-05-20 |
| BR112018017225A2 (pt) | 2019-01-15 |
| EP3419976A1 (en) | 2019-01-02 |
| AU2017222962A1 (en) | 2018-08-23 |
| WO2017144637A1 (en) | 2017-08-31 |
| US20190055233A1 (en) | 2019-02-21 |
| CN109071526B (zh) | 2023-02-28 |
| EA201891438A1 (ru) | 2019-01-31 |
| EP3419976B1 (en) | 2021-04-07 |
| AU2017222962B2 (en) | 2021-03-25 |
| CN109071526A (zh) | 2018-12-21 |
| CA3014572A1 (en) | 2017-08-31 |
| US10696668B2 (en) | 2020-06-30 |
| JP6971999B2 (ja) | 2021-11-24 |
| CA3014572C (en) | 2023-10-03 |
| US11591327B2 (en) | 2023-02-28 |
| ZA201804870B (en) | 2023-02-22 |
| KR20180132060A (ko) | 2018-12-11 |
| ES2879351T3 (es) | 2021-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807012QA (en) | Acid addition salts of piperazine derivatives | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201901445TA (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201807005VA (en) | Process for the separation of enantiomers of piperazine derivatives | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201903230QA (en) | TCRa HOMING ENDONUCLEASE VARIANTS | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201901477PA (en) | Compound for use in the treatment of neurogenic orthostatic hypotension |